Pathology & Oncology Research最新文献

{"title":"CD34 evaluation of microvasculature in lung adenocarcinoma and its microvascular density predicts postoperative tumor recurrence.","authors":"Zijian Qiu, Jiaji Wu, Guanchao Pang, Xia Xu, Jun Lin, Pingli Wang","doi":"10.3389/pore.2025.1611985","DOIUrl":"10.3389/pore.2025.1611985","url":null,"abstract":"<p><strong>Background: </strong>Angiogenesis is closely associated with tumor growth and metastasis, and microvascular density (MVD) is currently the clinical standard for evaluating tumor angiogenesis. Thus, the detection of intratumoral MVD is of great significance for understanding disease progression and predicting patient prognosis.</p><p><strong>Methods: </strong>Tumor tissue sections of 238 patients with lung adenocarcinoma (LUAD) who underwent radical surgery were retrospectively analyzed. Immunohistochemical (IHC) staining was carried out using a CD34 polyclonal antibody to determine intratumoral MVD, and the relationship of CD34-MVD with the clinicopathological characteristics and survival time of LUAD patients was analyzed.</p><p><strong>Results: </strong>CD34-MVD was associated with tumor size, lymph node metastasis, tumor recurrence, and patient survival status; patients with tumor size ≤3 cm (<i>P</i> = 0.015), negative for lymph node metastasis (<i>P</i> = 0.049), no tumor recurrence (<i>P</i> = 0.021), and survival (<i>P</i> = 0.042) had higher MVD. Survival analysis suggested that patients with high MVD had higher disease-free survival (log-rank <i>P</i> = 0.005) and overall survival (log-rank <i>P</i> = 0.004) compared to patients with low MVD. The Cox proportional hazards model showed that a high MVD (<i>P</i> = 0.022) reduced the risk of postoperative tumor recurrence in patients with LUAD.</p><p><strong>Conclusion: </strong>Decreased intratumoral CD34 positive microvessels were associated with tumor development in patients with LUAD. CD34-MVD is an independent risk factor affecting postoperative tumor recurrence in patients with LUAD and can be used as a prognostic indicator for this group of patients.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"31 ","pages":"1611985"},"PeriodicalIF":2.3,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11788009/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143190109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the correlation between pretreatment ¹⁸F-FDG PET/CT metabolic parameters and tumor-infiltrating lymphocyte levels in nonluminal breast cancer and impact on survival.","authors":"Muge Tamam, Halim Ozcevik, Gamze Kulduk, Merve Nur Acar Tayyar, Gunduzalp Bugrahan Babacan","doi":"10.3389/pore.2024.1612014","DOIUrl":"10.3389/pore.2024.1612014","url":null,"abstract":"<p><strong>Background and objectives: </strong>This study aims to evaluate the correlation between Tumor-Infiltrating Lymphocyte (TIL) levels and Fluorine-18 fluorodeoxyglucose (¹⁸F-FDG) metabolic parameters, including spleen and bone marrow FDG uptake and tumor heterogeneity in non-luminal breast cancers (NLBC), and to elucidate their association with survival outcomes.</p><p><strong>Methods: </strong>We retrospectively analyzed data from 100 females with stage 2-4 NLBC who underwent pretreatment ¹⁸F-FDG Positron emission tomography-computed tomography (PET/CT). TIL was scored based on Hematoxylin-Eosin-stained specimens and ¹⁸F-FDG PET metabolic parameters, including maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), liver, spleen, and bone marrow FDG uptake were calculated. Heterogeneity Index (HI)1, HI2, and HI3 indices were analyzed with FDG metabolic parameters. The association between these factors and overall survival was analyzed using multivariate Cox regression models.</p><p><strong>Results: </strong>TIL showed weak negative correlations with tumor size, tumor (T), and metastasis (M) stages. No significant correlation was found between TIL levels and overall SUV values. However, in stage 4, TIL correlated positively with liver, spleen, and bone marrow SUV values and negatively with heterogeneity indices (HI2, HI3). Higher tumor size, HI values, and Bone marrow-to-liver ratio (BLR) SUVmean were associated with increased mortality. A TIL cut-off value of <5 was linked to significantly worse survival.</p><p><strong>Conclusion: </strong>Our study demonstrates a strong connection between TIL, FDG metabolic parameters, and tumor heterogeneity, particularly in advanced NLBC. Although TIL is not generally associated with SUV values, its association with certain metabolic and heterogeneity indices suggests that it is important in influencing survival. Further research involving larger cohorts and diverse breast cancer subtypes is needed to validate these results.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"30 ","pages":"1612014"},"PeriodicalIF":2.3,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11750436/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143009889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NTRK amplification occurs frequently in pan-TRK immunopositive dedifferentiated liposarcomas.","authors":"Zoltán Lippai, Gergő Papp, Károly Szuhai, Johanna Sápi, Katalin Dezső, Zoltán Sápi","doi":"10.3389/pore.2024.1611993","DOIUrl":"10.3389/pore.2024.1611993","url":null,"abstract":"<p><p>The <i>neurotrophic tyrosine kinase receptor</i> (<i>NTRK</i>) gene family is of rising importance as their fusions are oncogenic, and specific target drugs are available to inhibit the chimera proteins. Pan-TRK antibody, which shows the overexpression of the <i>NTRK1-2-3</i> genes, is a useful tool to detect tumors with or without <i>NTRK</i> gene alterations, due to high negative predictive value. Though it is well known that pan-TRK immunopositivity is usually not connected to <i>NTRK</i> fusion, the role of other possible genetic alterations is under-researched. In our previous work, we found 3 <i>NTRK1</i> amplified cases out of 6 cases with recurrent <i>NTRK1</i> tyrosine kinase domain mutation pair, so we extended our investigation to a larger series to estimate amplification frequency. Pan-TRK immunopositivity was seen in 76 of the 132 dedifferentiated liposarcomas cases, followed by <i>NTRK1-2-3</i> break-apart FISH tests in 76 pan-TRK positive cases to detect oncogenic fusions or other copy number alterations of these genes. None of the pan-TRK immunopositive dedifferentiated liposarcomas showed absolutely certain sign of fusion, however, 18 (28%) cases showed amplification of one of the genes, 13 had polysomy, 34 were normal, 11 were not evaluable. The extent of pan-TRK immunoreaction showed a positive correlation (p = 0.002) with the <i>NTRK</i> status found by FISH. Analyzing publicly available data from large series of 265 liposarcoma samples consisting of both well-differentiated and dedifferentiated liposarcoma case, 23 (8.6%) cases showed a mutual exclusive amplification of the <i>NTRK</i> genomic loci in a non-preselected, independent patient population indicating that our findings are presented in other cohorts. Our results underline the so far not revealed frequent occurrence of <i>NTRK</i> amplifications which might be important in the TRK inhibition therapy.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"30 ","pages":"1611993"},"PeriodicalIF":2.3,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11745873/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143009893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-ceramide antibody and sphingosine-1-phosphate as potential biomarkers of unresectable non-small cell lung cancer.","authors":"Lilla Bűdi, Dániel Hammer, Rita Varga, Veronika Müller, Ádám Domonkos Tárnoki, Dávid László Tárnoki, Martina Mészáros, András Bikov, Péter Horváth","doi":"10.3389/pore.2024.1611929","DOIUrl":"10.3389/pore.2024.1611929","url":null,"abstract":"<p><strong>Objectives: </strong>Spingosine-1-phosphate (S1P) and ceramides are bioactive sphingolipids that influence cancer cell fate. Anti-ceramide antibodies might inhibit the effects of ceramide. The aim of this study was to assess the potential role of circulating S1P and anti-ceramide antibody as biomarkers in non-small cell lung cancer (NSCLC).</p><p><strong>Methods: </strong>We recruited 66 subjects (34 controls and 32 patients with NSCLC). Patient history and clinical variables were taken from all participants. Venous blood samples were collected to evaluate plasma biomarkers. If bronchoscopy was performed, bronchial washing fluid (BWF) was also analyzed. We measured the levels of S1P and anti-ceramide antibody with ELISA.</p><p><strong>Results: </strong>S1P levels were significantly higher in the NSCLC group (3770.99 ± 762.29 ng/mL vs. 366.53 ± 249.38 ng/mL, patients with NSCLC vs. controls, respectively, <i>p</i> < 0.001). Anti-ceramide antibody levels were significantly elevated in the NSCLC group (278.70 ± 19.26 ng/mL vs. 178.60 ± 18 ng/mL, patients with NSCLC vs. controls, respectively, <i>p</i> = 0.007). Age or BMI had no significant effect on anti-ceramide antibody or S1P levels. BWF samples had higher levels of anti-ceramide antibody (155.29 ± 27.58 ng/mL vs. 105.87 ± 9.99 ng/mL, patients with NSCLC vs. controls, respectively, <i>p</i> < 0.001). Overall survival (OS) was 13.36 months. OS was not affected by anti-ceramide antibody or S1P levels.</p><p><strong>Conclusion: </strong>Higher levels of S1P and anti-ceramide antibody were associated with active cancer. These results suggest that sphingolipid alterations might be important features of NSCLC.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"30 ","pages":"1611929"},"PeriodicalIF":2.3,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11742942/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143009888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Examination of non-conventional dysplasias adjacent to colorectal adenocarcinoma in patients with IBD.","authors":"Szintia Almási, Zsófia Balajthy, Bence Baráth, Zsófia Krisztina Török, Panna Szaszák, Tamás Lantos, Bence Kővári, Anita Sejben","doi":"10.3389/pore.2024.1611978","DOIUrl":"10.3389/pore.2024.1611978","url":null,"abstract":"<p><strong>Objective: </strong>Recently, several non-conventional variants of IBD-associated dysplasia have been described; however, their prevalence in Central-Eastern Europe is unknown. We aimed to perform a retrospective pilot study by re-evaluating several IBD-associated adenocarcinoma cases to survey the incidence of adjacent non-conventional dysplasia and validate that recent North American findings may apply to a European population.</p><p><strong>Methods: </strong>Retrospectively, 28 randomly chosen cases of IBD-associated adenocarcinomas diagnosed between 2010 and 2022 were re-evaluated. The patient's sex, age (at the diagnosis of IBD and neoplasia), type of IBD, type of specimen [biopsy (n = 8)/surgical specimen (n = 20)], histological type, grade, localisation, stage, disease-free (DFS) and overall survival (OS) were obtained. Statistical analyses were carried out by using Mann-Whitney (continuous variables), Fisher's exact (categorical variables), Kaplan-Meier (DFS/OS curves), and logrank test (survival curves).</p><p><strong>Results: </strong>Exclusively, conventional dysplasia was observed in 11, and non-conventional dysplasia in 8 patients. Combined conventional and non-conventional dysplasia was detected in 9 patients. Non-conventional dysplasia showing a combination of multiple subtypes was noted in 10 cases. Altogether, 25 non-conventional dysplastic foci were identified, which were diagnosed as hypermucinous (n = 9), goblet cell-deficient (n = 6), serrated not otherwise specified (NOS) (n = 6), and traditional serrated adenoma-like (n = 4). The majority of non-conventional dysplasias were associated with ulcerative colitis (n = 12). Mucinous adenocarcinoma was exclusively associated with non-conventional dysplasia, while medullary carcinoma was only with conventional dysplasias (<i>p = 0.014</i> and <i>0.041</i>).</p><p><strong>Conclusion: </strong>Based on our results, non-conventional dysplasia is common (60%) adjacent to IBD-associated adenocarcinomas in a Central-Eastern European population and may be detected in biopsies. As multiple recent publications reported evidence of a worse prognosis and more common flat morphology compared to conventional dysplasias, their recognition is of great importance, and stricter follow-up with random biopsy samples may be considered.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"30 ","pages":"1611978"},"PeriodicalIF":2.3,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11738611/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143009891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction: Effects of gallotannin-enriched extract of Galla Rhois on the activation of apoptosis, cell cycle arrest, and inhibition of migration ability in LLC1 cells and LLC1 tumors.","authors":"","doi":"10.3389/pore.2024.1612042","DOIUrl":"https://doi.org/10.3389/pore.2024.1612042","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.3389/pore.2021.588084.].</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"30 ","pages":"1612042"},"PeriodicalIF":2.3,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11670366/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142896692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Invasive micropapillary carcinoma of the breast and invasive breast carcinoma of no special type: a comparison of claudin proteins' expression and its impact on survival.","authors":"Zsófia Kramer, András Budai, Adrián Pesti, Janina Kulka, Anna-Mária Tőkés","doi":"10.3389/pore.2024.1611987","DOIUrl":"10.3389/pore.2024.1611987","url":null,"abstract":"<p><p>Invasive micropapillary carcinoma of the breast is characterized by clusters of cells presenting with inverted polarity. Although the apico-basal polarity is a fundamental property of the epithelium, the biological alterations leading to the inside-out pattern observed in invasive micropapillary carcinoma (IMPC) remain mostly unknown. The regulation of tight junctions in polarity formation and maintenance is acknowledged. By using immunohistochemistry, we have analysed claudin-1, -3, -4, and -7 tight junction proteins expression and their prognostic value on IMPCs and compared them to invasive breast carcinomas of no special type (IBC-NST) tumors. Our cohort consisted of 37 IMPCs, 36 IBC-NST and 9 mixed IMPC/IBC-NST tumors. Two scoring systems were used to quantify protein expression: a 4-tier scoring system and the H-score method. Distant metastasis free survival (DMFS) intervals and overal survival (OS) data were used for prognosis evaluation. The analysed samples were characterized mainly by low or no claudin-1 expression whereas claudins-3, -4 and -7 showed variable positivity. We have found no significant differences in claudin-3 and -4 protein expression between IMPC and IBC-NST groups with either scoring methods, however high claudin-7 expression was found in significantly more IMPCs than IBC-NST tumors according to the H-score system (<i>p</i> = 0.02). The 4-tier scoring method revealed association of claudin-7 expression with molecular tumor subtypes (<i>p</i> = 0.001). IMPC and IBC-NST tumors did not show difference in DMFS (<i>p</i> = 0.70). In the analysis of pure IMPC and IBC-NST tumors, positive/high claudin-4 protein expression was significantly associated with shorter DMFS (<i>p</i> = 0.02/<i>p</i> = 0.008, respectively according to the two scoring methods). Claudin-3 and claudin-7 expression showed no association with DMFS or OS. Changes in epithelial polarity seem not to be related to claudin-1, -3, and -4 expression. Increased claudin-4 expression may have a role in breast cancer progression.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"30 ","pages":"1611987"},"PeriodicalIF":2.3,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11646764/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142838470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination of farnesyl-transferase inhibition with KRAS G12D targeting breaks down therapeutic resistance in pancreatic cancer.","authors":"Eszter Molnár, Marcell Baranyi, Krisztina Szigeti, Luca Hegedűs, Fanni Bordás, Zsófia Gábriel, Gréta Petényi, József Tóvári, Balázs Hegedűs, József Tímár","doi":"10.3389/pore.2024.1611948","DOIUrl":"10.3389/pore.2024.1611948","url":null,"abstract":"<p><p>Pancreatic adenocarcinoma is one of the deadliest forms of cancer with no effective therapeutic options. A KRAS mutation can be found in up to 90% of all pancreatic tumors, making it a promising therapeutic target. The introduction of new KRAS inhibitors has been a milestone in the history of KRAS mutant tumors; however, therapeutic resistance limits their efficacy. Thus, new therapeutic options, including combination therapies, are urgently needed. Recently, we have shown that KRAS G12C inhibitors in combination with farnesyl-transferase inhibitors exert synergistic antitumor effects. Here, we provide evidence for the feasibility of this combinational approach to break down resistance in KRAS G12D mutant pancreatic cancer. Although we have shown that the 3D environment dramatically sensitizes cells to MRTX1133 treatment, the synergistic effect of this drug combination is present in both 2D and 3D in the PANC1 pancreatic adenocarcinoma model, which showed high resistance to MRTX1133 in 2D. The effects of the combination treatment show an association with the inhibition of farnesylated regulatory proteins, including HRAS and RHEB, along with the expression level of KRAS. Our study warrants further investigation for the potential applicability of KRAS G12D inhibitors in combination with farnesyl-transferase inhibitors for the treatment of KRAS mutant pancreatic adenocarcinoma.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"30 ","pages":"1611948"},"PeriodicalIF":2.3,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11646715/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142838361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of limb ischemic preconditioning on the incidence of vein thrombosis in patients with peripherally inserted central catheter.","authors":"Han Zhao, Changhua Kou, Hao Zhao, Qing Liu, Maosheng He, Cong Wang, Saisai Zhu, Li Ma, Yun Wang","doi":"10.3389/pore.2024.1611596","DOIUrl":"10.3389/pore.2024.1611596","url":null,"abstract":"<p><strong>Background: </strong>Peripherally inserted central catheters (PICC) are increasingly used in clinical practice, which also leads to an increased incidence of PICC-related thrombosis. Local thrombus formation could be prevented by limb ischemic preconditioning (IPC). This study aimed to determine whether IPC can prevent deep vein thrombosis in patients with PICC.</p><p><strong>Methods: </strong>A total of 600 breast cancer patients receiving PICC were randomized into two groups between July 2016 and July 2018 at the Department of Radiation Oncology. In the preconditioning group, 5 min of ischemic preconditioning was performed three times before PICC, whereas no preconditioning was performed in the sham group. The coagulation function levels, the PICC-related complications, the length of hospital stay, the cost of hospitalization, and the satisfaction of patients were compared.</p><p><strong>Results: </strong>The coagulation function levels of patients in the preconditioning group were more normal than in patients from the sham group. In total, 56/300 patients in the sham group had presence of PICC-related thrombosis, with only 23/300 in the IPC group, with no significant difference in other complications between the two groups. However, a longer hospital stay was observed in the sham group compared to the IPC group. Moreover, the cost of hospitalization was also reduced in the IPC group, which also improved the satisfaction of patients.</p><p><strong>Conclusion: </strong>Limb ischemic preconditioning may attenuate the severity of vein thrombosis in patients with PICC, which contributes to reducing the incidence of PICC-related thrombosis in clinical practice.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"30 ","pages":"1611596"},"PeriodicalIF":2.3,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11602314/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142751451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction: The <i>Plasmodium</i> circumsporozoite protein, a novel NF-κB inhibitor, suppresses the growth of SW480.","authors":"","doi":"10.3389/pore.2024.1612018","DOIUrl":"https://doi.org/10.3389/pore.2024.1612018","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.1007/s12253-012-9519-7.].</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"30 ","pages":"1612018"},"PeriodicalIF":2.3,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11588444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142731811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}